No products in the cart.
We are a leading biotech company in China. Our team has more than 20 years of experience in R&D, production and management of leading enterprises. The company’s pharmaceutical sector focuses on the development of diabetes biopharmaceuticals, using genetic engineering to produce insulin and GLP-1 biopharmaceuticals, while developing other new biological drugs. We actively explore new ideas for stem cell therapy and intestinal microbial therapy for diabetes, and have obtained investment from well-known domestic professional companies in the field of diabetes treatment and government-guided funds. The relevant cutting-edge technologies have been supported by German and American laboratories.
Peptide APIs / Protein APIs
Liraglutide, Semaglutide, Tezorparatide / Recombinant insulin aspart, recombinant insulin degludec, recombinant Icodec insulin
Proteases
Recombinant trypsin, recombinant aprotinin, recombinant enterokinase, recombinant proteinase K, aminopeptidase
Cell culture factors / CGT products
Recombinant human insulin, EGF, FGF2, IGF-1 LR3, transferrin, Noggin / pluripotent nuclease, T7 RNA polymerase, Cas9 enzyme Various forms of Tirzepatide、Retatrutide 、HGH NAD+
About
Some lines about us
Our Goal
our goal is simple: to be your trusted high-quality supplier by offering top-notch products at affordable prices. We strive to meet and exceed your expectations with every order, ensuring that you receive the best value without compromising on quality.
With a focus on both excellence and cost-effectiveness, we aim to build lasting partnerships by providing reliable products that support your business success. Whether you’re looking for industry-specific solutions or general products, we’re here to deliver with efficiency, integrity, and the highest standards of service.
Choose us for quality, affordability, and commitment to your satisfaction.
1. Development of different host expression platform technologies (E. coli, mammalian cells and Bacillus subtilis);
2. Development and optimization of chromatography purification processes (affinity chromatography, ion exchange chromatography, hydrophobic chromatography, mixed mode chromatography);
3. Protein CMC quality evaluation system that meets the requirements of biological stock solution and protein products with stable activity and purity output;
4. Pilot-scale and 100L-level process technology transfer;
5. Protein activity analysis and quality platform capabilities that meet GMP requirements.
Rich R&D and production experience:
The company’s upstream and downstream process development teams have accumulated technology over the years and have rich experience in both pharmaceuticals and industrial products.
Corporate culture
Dedicated to the development of diabetes biopharmaceuticals
Innovation, self-drive, teamwork, win-win
